logo
Jim Cramer on Medtronic plc (MDT): 'I Like This Medical Device Powerhouse'

Jim Cramer on Medtronic plc (MDT): 'I Like This Medical Device Powerhouse'

Yahoo20-05-2025

We recently published a list of . In this article, we are going to take a look at where Medtronic plc (NYSE:MDT) stands against other stocks on Jim Cramer's radar
On Friday's episode of Mad Money, Jim Cramer reflected on this week's market performance, with attention to upcoming earnings reports and broader market sentiment.
'Now we've been on a real rebound since post-Liberation Day meltdown back in the first week of April, with tech leading the way after really taking it on the chin.'
READ ALSO Jim Cramer Recently Commented On These 12 Stocks and Jim Cramer Put These 8 Stocks Under a Microscope Recently
According to Cramer, the rebound has been largely driven by tech stocks, which had previously been under pressure. However, he expressed uncertainty about whether that trend will hold, as he mentioned that the tech sector has been relatively quiet in terms of news, aside from a keynote from Jensen Huang. Looking ahead, Cramer noted that more retail earnings are expected this week.
'But here's the bottom line: Unless we get news of new hostilities in the trade war with China, I think this market's propensity will still be to go higher, even though we are overbought. And even with this late-night credit rating downgrade of the US debt, which is very quizzical to me, I think we're containing the downside of the economy, and that means no recession, which tells me the negativity may be out of sync with the reality. That's often the best kind of market…'
For this article, we compiled a list of 15 stocks that were discussed by Jim Cramer during the episodes of Mad Money aired on May 16. We listed the stocks in the order that Cramer mentioned them. We also provided hedge fund sentiment for each stock as of the fourth quarter of 2024, which was taken from Insider Monkey's database of over 1,000 hedge funds.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points ().
A surgeon in a modern operating room holding advanced medical devices with a sense of purpose and accuracy.
Number of Hedge Fund Holders: 67
Noting Medtronic plc (NYSE:MDT) stock's inconsistency, Cramer advised investors to 'wait and see'.
'Also, Wednesday, we hear from Medtronic, and I like this medical device powerhouse, but the stock's been inconsistent even as the numbers tend to be pretty darn strong. That means it's hard to game. Another one, I gotta say, wait and see.'
Medtronic (NYSE:MDT) is a well-known global company in medical technology that specializes in the development and sale of a broad range of medical devices and treatments. For the fiscal year 2025, the company expects organic revenue growth between 4.75% and 5% for the year.
Additionally, Medtronic (NYSE:MDT) expects its diluted non-GAAP EPS to fall between $5.44 and $5.50, an expected increase of approximately 4.6% to 5.8% compared to the previous year.
Overall, MDT ranks 11th on our list of stocks on Jim Cramer's radar. While we acknowledge the potential of MDT as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than MDT and that has 100x upside potential, check out our report about this cheapest AI stock.
READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.
Disclosure: None. This article is originally published at Insider Monkey.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

2 Growth Stocks to Stash and 1 to Question
2 Growth Stocks to Stash and 1 to Question

Yahoo

time33 minutes ago

  • Yahoo

2 Growth Stocks to Stash and 1 to Question

Growth is a hallmark of all great companies, but the laws of gravity eventually take hold. Those who rode the COVID boom and ensuing tech selloff in 2022 will surely remember that the market's punishment can be swift and severe when trajectories fall. Deciphering which businesses can sustain their high growth rates is a challenge for even the most seasoned professionals, which is why we started StockStory. On that note, here are two growth stocks expanding their competitive advantages and one climbing an uphill battle. One-Year Revenue Growth: +25.3% Founded in 2009 by enterprise software veteran Tom Seibel, (NYSE:AI) provides software that makes it easy for organizations to add artificial intelligence technology to their applications. Why Does AI Fall Short? 15.5% annual revenue growth over the last three years was slower than its software peers Extended payback periods on sales investments suggest the company's platform isn't resonating enough to drive efficient sales conversions Historical operating margin losses point to an inefficient cost structure stock price of $25.72 implies a valuation ratio of 7.4x forward price-to-sales. Dive into our free research report to see why there are better opportunities than AI. One-Year Revenue Growth: +32.3% Founded in 2014 and named after the dreaded first day of the work week, (NASDAQ:MNDY) is a software-as-a-service platform that helps organizations plan and track work efficiently. Why Is MNDY a Good Business? ARR trends over the last year show it's maintaining a steady flow of long-term contracts that contribute positively to its revenue predictability Software is difficult to replicate at scale and results in a best-in-class gross margin of 89.5% Strong free cash flow margin of 30.4% enables it to reinvest or return capital consistently is trading at $305 per share, or 12.7x forward price-to-sales. Is now a good time to buy? Find out in our full research report, it's free. One-Year Revenue Growth: +20% Founded in 2010 and named for a combination of 'docs' and 'proximity', Doximity (NYSE: DOCS) is the leading social network for U.S. medical professionals. Why Should DOCS Be on Your Watchlist? Billings have averaged 23.5% growth over the last year, showing it's securing new contracts that could potentially increase in value over time Well-designed software integrates seamlessly with other workflows, enabling swift payback periods on marketing expenses and customer growth at scale DOCS is a free cash flow machine with the flexibility to invest in growth initiatives or return capital to shareholders At $58.44 per share, Doximity trades at 19x forward price-to-sales. Is now the right time to buy? See for yourself in our comprehensive research report, it's free. Market indices reached historic highs following Donald Trump's presidential victory in November 2024, but the outlook for 2025 is clouded by new trade policies that could impact business confidence and growth. While this has caused many investors to adopt a "fearful" wait-and-see approach, we're leaning into our best ideas that can grow regardless of the political or macroeconomic climate. Take advantage of Mr. Market by checking out our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today for free.

Global Blue Announces NYSE Delisting Proceedings for Warrants
Global Blue Announces NYSE Delisting Proceedings for Warrants

Yahoo

timean hour ago

  • Yahoo

Global Blue Announces NYSE Delisting Proceedings for Warrants

SIGNY, Switzerland, June 11, 2025--(BUSINESS WIRE)--Global Blue Holding AG ("Global Blue") announces that on June 6, 2025, it was notified by the New York Stock Exchange ("NYSE") of its intention to initiate delisting proceedings for Global Blue's warrants, which are listed under the ticker symbol " The NYSE subsequently issued a press release on June 9, 2025, confirming that trading in the warrants will be suspended with immediate effect due to consistently low trading price levels, in accordance with Section 802.01D of the NYSE Listed Company Manual. Global Blue does not intend to appeal this determination. This action relates solely to the company's warrants and does not affect the listing of Global Blue's ordinary shares, which will continue to trade on the NYSE under the ticker symbol "GB". ABOUT GLOBAL BLUE Global Blue is the business partner for the shopping journey, providing technology and services to enhance the experience and drive performance. With over 40 years of expertise, today we connect thousands of retailers, acquirers, and hotels with nearly 80 million consumers across 53 countries, in three industries: Tax Free Shopping, Payments and Post-Purchase solutions. With over 2,000 employees, Global Blue generated €33bn Sales in Store and €508M revenue in FY 2024/25. Global Blue is listed on the New York Stock Exchange. For more information, please visit View source version on Contacts For more information please contact: MEDIA Virginie Alem – Chief Marketing Officer and Chief Operating Officer JapanMail: valem@ Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data

LiveRamp and Walgreens Advertising Group Deliver Business Growth for Advertisers Through Robust Data Collaboration Partnership
LiveRamp and Walgreens Advertising Group Deliver Business Growth for Advertisers Through Robust Data Collaboration Partnership

Yahoo

timean hour ago

  • Yahoo

LiveRamp and Walgreens Advertising Group Deliver Business Growth for Advertisers Through Robust Data Collaboration Partnership

WAG advertisers can now accelerate audience creation, activation, and measurement with flexibility and speed SAN FRANCISCO, June 11, 2025--(BUSINESS WIRE)--LiveRamp (NYSE: RAMP), the leading data collaboration partner, today announced it is powering Walgreens Advertising Group's (WAG) clean room solution. The partnership enables WAG, the retail media division of Walgreens, to increase access to its first-party data at speed, scale audience insights, and offer more transparency and control to advertisers. This enables brands to enhance media measurement across all platforms in the digital ecosystem and improve ROI with faster time-to-value. LiveRamp's data collaboration network enables WAG to unlock new insights, accelerate performance, and drive business growth. By strengthening WAG's identity infrastructure and ecosystem connectivity, LiveRamp extends the efficiency of WAG's first-party data solutions to improve personalization capabilities, access data at scale, and deliver real-time campaign performance insights. Using the LiveRamp Clean Room, granular campaign measurement is also possible across offsite publishers and walled gardens. These enhancements bring a multitude of new benefits to WAG advertisers and partners, including: Expanded collaboration based on Walgreens' unique national customer base, including more than 101 million myWalgreens loyalty members who generate billions of signals daily from online, in-store, and delivery activities Self-service access to syndicated and custom audience creation for more personalized targeting across the customer journey, using Walgreens' rich data combined with brands' desired media channels Activation at greater speed and scale across programmatic, walled garden, CTV, social, search, and buy- and sell-side platforms Consolidated measurement to optimize the performance of managed and self-service campaigns with more accurate and granular insights Enhanced interoperability, flexibility, and data governance to minimize the movement of data while collaborating with partners "We're committed to empowering our partners with a transparent, self-service approach that allows them to leverage data on their own terms—with privacy in mind," said Abishake Subramanian, Group Vice President of Customer Marketing and Media Monetization at Walgreens. "Our focus is on investing in leading technologies that enhance data portability, audience scalability, and campaign measurability—while executing responsibly to create more meaningful experiences for Walgreens shoppers. With some of the most integrated and interoperable solutions in the marketplace that support upholding strict privacy protections, partners like LiveRamp play a key role in helping WAG deliver on this vision." "LiveRamp and WAG are helping advertisers get more from their media network investment by improving access, activation, and measurement across any partner or platform with speed and scale," said Vihan Sharma, Chief Revenue Officer at LiveRamp. "WAG is already a highly differentiated offering in retail and healthcare that decouples data and media. Advertisers can now further deepen their customer understanding, improve cross-channel performance, and enhance closed-loop measurement to drive ROI." To learn more about the Walgreens Advertising Group, including the new offerings, visit Uncover the brand-building power of media networks at About Walgreens Founded in 1901, Walgreens ( has a storied heritage of caring for communities for generations, and proudly serves nearly 9 million customers and patients each day across its approximately 8,500 stores throughout the U.S. and Puerto Rico, and leading omni-channel platforms. Walgreens has approximately 220,000 team members, including nearly 90,000 healthcare service providers, and is committed to being the first choice for retail pharmacy and health services, building trusted relationships that create healthier futures for customers, patients, team members and communities. Walgreens is the flagship U.S. brand of Walgreens Boots Alliance, Inc. (Nasdaq: WBA), an integrated healthcare, pharmacy and retail leader. Its retail locations are a critical point of access and convenience in thousands of communities, with Walgreens pharmacists playing a greater role as part of the healthcare system and patients' care teams than ever before. Walgreens Specialty Pharmacy provides critical care and pharmacy services to millions of patients with rare disease states and complex, chronic conditions. About LiveRamp LiveRamp is the leading data collaboration partner, empowering marketers and media owners to deliver exceptional experiences and drive measurable performance everywhere it matters with the world's most powerful data collaboration network. Built on a foundation of strict neutrality, unmatched interoperability, and global scale, LiveRamp enables organizations to maximize measurable outcomes and create lasting business value. Trusted by the world's leading brands, retailers, financial services providers, and healthcare innovators, LiveRamp is shaping the future of responsible data collaboration in an AI-driven, outcomes-focused world. LiveRamp is headquartered in San Francisco, California, with offices worldwide. Learn more at View source version on Contacts Media Contacts Kamara Turnermedia@ Michelle MillsapPR@

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store